State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis

References

• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–2038.
   PubMed Web of Science ®Google Scholar
• Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4:S265–72.
   PubMedGoogle Scholar
• Silman AJ, Macgregor AJ, Thomson W, et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Rheumatology. 1993;32:903–907.
   Web of Science ®Google Scholar
• Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheumatism. 1987;30:1205–1213.
   PubMed Web of Science ®Google Scholar
• Okada Y, Wu D, Trynka G, et al.; The RACI consortium, the GARNET consortium. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506:376–381. .
   PubMed Web of Science ®Google Scholar
• Okada Y, Eyre S, Suzuki A, et al. Genetics of rheumatoid arthritis: 2018 status. Ann Rheum Dis. 2019;78:446–453.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117–1127.
   PubMed Web of Science ®Google Scholar
• Malemud J. Monosodium urate and tumor necrosis factor-α increase apoptosis in human chondrocyte cultures. Rheumatol Curr Res. 2012;02. DOI:10.4172/2161-1149.1000113.
   Google Scholar
• Biffi G, Oni TE, Spielman B, et al. IL1-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019;9:282–301.
   PubMed Web of Science ®Google Scholar
• Malemud C. Negative regulators of JAK/STAT signaling in rheumatoid arthritis and osteoarthritis. IJMS. 2017;18:484.
   Google Scholar
• Milici AJ, Kudlacz EM, Audoly L, et al. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther. 2008;10:R14.
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 1998;93:373–383.
   PubMed Web of Science ®Google Scholar
• Macchi P, Villa A, Giliani S, et al. Mutations of JAK-3 gene in patients with autosomal severe combined immunodeficiency (SCID). Nature. 1995;377(6544):65-68.
   Web of Science ®Google Scholar
• Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 1995;270:797–800.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Biehl A, Gadina M, et al. JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77:521–546.
   PubMed Web of Science ®Google Scholar
• Olbrich P, Freeman AF. STAT1 and STAT3 mutations: important lessons for clinical immunologists. Expert Rev Clin Immunol. 2018;14:1029–1041.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheumatism. 2009;60:1895–1905.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.
   PubMed Web of Science ®Google Scholar
• Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377–2386.
   PubMed Web of Science ®Google Scholar
• Kremer J, Li Z-G, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized Trial. Ann Intern Med. 2013;159:253.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheumatism. 2013;65:559–570.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–519.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457–468.
   PubMed Web of Science ®Google Scholar
• Lamba M, Wang R, Fletcher T, et al. Extended-release once-daily formulation of tofacitinib: evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food: pharmacokinetics of extended-release tofacitinib. J Clin Pharmacol. 2016;56:1362–1371.
   PubMed Web of Science ®Google Scholar
• Kubo S, Yamaoka K, Amano K, et al. Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study. Rheumatology. 2017;56:1293–1301.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76:1253–1262.
   PubMed Web of Science ®Google Scholar
• Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1843–1847.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Wouters AG, Choy EH, et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial: effect of LZV in ra patients prior to treatment with tofacitinib. Arthritis Rheumatol. 2017;69:1969–1977.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Wouters A, Choy EH, et al. Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib. Ann Rheum Dis. 2020;79:669–671.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374:1243–1252.
   PubMed Web of Science ®Google Scholar
• Dougados M, van der Heijde D, Chen Y-C, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76:88–95.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652–662.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment: baricitinib in patients with early rheumatoid arthritis. Arthritis Rheumatol. 2017;69:506–517.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Dougados M, Chen Y-C, et al. Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open. 2018;4:e000662.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Taylor PC, Drescher E, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015;74:333–340.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Emoto K, Cai Z, et al. Efficacy and safety of baricitinib in japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol. 2016;43:504–511.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Fautrel B, Keystone EC, et al. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78:890–898.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Smolen JS, Weinblatt ME, et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase iib study in patients with rheumatoid arthritis and an inadequate response to methotrexate: ABT-494 in patients with rheumatoid arthritis and inadequate response to methotrexate. Arthritis Rheumatol. 2016;68:2857–2866.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Emery P, Camp HS, et al. A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy: ABT-494 in patients with ra and inadequate response to anti-tnf therapy. Arthritis Rheumatol. 2016;68:2867–2877.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:2503–2512.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391:2513–2524.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303–2311.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Pangan AL, Song I, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase iii, double‐blind, randomized controlled trial. Arthritis Rheumatol. 2019;71:1788–1800.
   PubMed Web of Science ®Google Scholar
• Kameda H, Takeuchi T, Yamaoka K, et al. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Rheumatology. 2020;keaa084. DOI:10.1093/rheumatology/keaa084.
   PubMedGoogle Scholar
• Song GG, Choi SJ, Lee YH. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis. 2019;22:1563–1571.
   PubMed Web of Science ®Google Scholar
• Van RL, Galien R, van der Aar EM, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. JI. 2013;191:3568–3577.
   Google Scholar
• Westhovens R, Taylor PC, Alten R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017;76:998–1008.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017;76:1009–1019.
   PubMed Web of Science ®Google Scholar
• Combe B, Kivitz A, Tanaka Y, et al. Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: finch1 primary outcome results [abstract]. Arthritis Rheumatol. 2019;71. Avaialble from: https://acrabstracts.org/abstract/efficacy-and-safety-of-filgotinib-for-patients-with-rheumatoid-arthritis-with-inadequate-response-to-methotrexate-finch1-primary-outcome-results/.
   Web of Science ®Google Scholar
• Genovese MC, Kalunian K, Gottenberg J-E, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322:315.
   PubMed Web of Science ®Google Scholar
• Ito M, Yamazaki S, Yamagami K, et al. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model. J Pharmacol Sci. 2017;133:25–33.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Iwasaki M, et al. Efficacy and safety of the oral janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 2016;75:1057–1064.
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Gutierrez‐Ureña SR, Poiley J, et al. Peficitinib, a JAK inhibitor, in the treatment of moderate‐to‐severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheumatol. 2017;69:709–719.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Greenwald M, Codding C, et al. Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease‐modifying antirheumatic drugs in the treatment of moderate‐to‐severe rheumatoid arthritis. Arthritis Rheumatol. 2017;69:932–942.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis. 2019;78:1320–1332.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis. 2019;78:1305–1319.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Greenwald MW, Gutierrez-Ureña SR, et al. Two-year safety and effectiveness of peficitinib in moderate-to-severe rheumatoid arthritis: a phase IIb, open-label extension study. Rheumatol Ther. 2019;6:503–520.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Tanaka S, et al. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. Arthritis Res Ther. 2020;22(47). DOI:10.1186/s13075-020-2125-2
   Google Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020.: annrheumdis-2019-216655. DOI:10.1136/annrheumdis-2019-216655.
   Google Scholar
• Mahajan S, Hogan JK, Shlyakhter D, et al. VX-509 (Decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease. J Pharmacol Exp Ther. 2015;353:405–414.
   PubMed Web of Science ®Google Scholar
• Farmer LJ, Ledeboer MW, Hoock T, et al. Discovery of VX-509 (Decernotinib): a potent and selective janus kinase 3 inhibitor for the treatment of autoimmune diseases. J Med Chem. 2015;58:7195–7216.
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Damjanov NS, Kivitz AJ, et al. Double‐blind, placebo‐controlled, twelve‐week, dose‐ranging study of decernotinib, an oral selective JAK‐3 Inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheumatol. 2015;67:334–343.
   PubMed Web of Science ®Google Scholar
• Genovese MC, van Vollenhoven RF, Pacheco-Tena C, et al. VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in combination with methotrexate in patients with rheumatoid arthritis: VX-509 with methotrexate for rheumatoid arthritis. Arthritis Rheumatol. 2016;68:46–55.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis: ACR RA treatment recommendations. Arthritis Rheumatol. 2016;68:1–26.
   PubMed Web of Science ®Google Scholar
• El Jammal T, Gerfaud-Valentin M, Sève P, et al. Inhibition of JAK/STAT signaling in rheumatologic disorders: the expanding spectrum. Joint Bone Spine. 2019;S1297319X19301265. DOI:10.1016/j.jbspin.2019.09.005
   Web of Science ®Google Scholar
• Yamaoka K. Tofacitinib for the treatment of rheumatoid arthritis: an update. Expert Rev Clin Immunol. 2019;15:577–588.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Takeuchi T, Schiff M, et al. Efficacy and safety of long‐term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate. Arthritis Care Res. 2020;72:1112–1121.
   PubMed Web of Science ®Google Scholar
• Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70:404–413.
   PubMed Web of Science ®Google Scholar
• van Mulligen E, de Jong PHP, Kuijper TM, et al. Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study. Ann Rheum Dis. 2019;78:746–753.
   PubMed Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T, et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398.
   PubMed Web of Science ®Google Scholar
• Reddy KR, Beavers KL, Hammond SP, et al. American gastroenterological association institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215–219.
   PubMed Web of Science ®Google Scholar
• Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum. 2016;46:71–80.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Kremer JM, Emery P, et al. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Ann Rheum Dis. 2018;77:988–995.
   PubMed Web of Science ®Google Scholar